Ma			
	ur Name: Jing Yu ohen	lung adlenocarcino	oma patient with ZGFR mutations benefitied
	nuscript Title: Advanced		1 1:0 1 1 ating 1 marked Maguapie
via	nuscript number (if known)	: AIM-10-711-1003 644	after osimertinib Vesis+andi a case ve
			ofter osimeriming vest the cost
n •	he blace an "X" next to the	we ask you to disclose a	Il relationships/activities/interests listed below that are
n t	ated to the content of your	, we ask you to disclose a manuscript "Related" me	eans any relation with for-profit or not-for-profit third
			of the manuscript. Disclosure represents a commitment
n i	transparency and does not i	necessarily indicate a hias	If you are in doubt about whether to list a
	ationship/activity/interest,		
Cit	actionismp, activity, interest,	ne is preferable that you a	
'he	following questions apply	to the author's relationsh	nips/activities/interests as they relate to the current
	nuscript only.	to the dutilor 5 relations.	
110	······································		
h	e author's relationships/acti	vities/interests should be	e defined broadly. For example, if your manuscript pertain
			e all relationships with manufacturers of antihypertensive
	dication, even if that medic		
	dication, even in that medic	ation is not inclinioned in	The management
n i	tom #1 holow report all su	anort for the work report	ed in this manuscript without time limit. For all other item
	time frame for disclosure i		ed in this manuscript without time inne. For an other reci
HE	time trame for disclosure i	s the past 50 months.	
	<b>网络红色 医性多形 经股份</b>	Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		Horie lada rows as	
		needed)	
		Name of the control o	al planning of the work
	All support for the present	needed)	al planning of the work
	All support for the present manuscript (e.g., funding,	needed) Time frame: Since the initi	al planning of the work
	manuscript (e.g., funding, provision of study materials,	needed) Time frame: Since the initi	al planning of the work
	manuscript (e.g., funding,	needed) Time frame: Since the initi	al planning of the work
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	needed) Time frame: Since the initi	al planning of the work
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	needed) Time frame: Since the initi	al planning of the work
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	needed) Time frame: Since the initi	al planning of the work
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	needed) Time frame: Since the initiNone	
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	needed) Time frame: Since the initiNone  Time frame: par	
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from	needed) Time frame: Since the initiNone	
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated	needed) Time frame: Since the initiNone  Time frame: par	
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).	needed) Time frame: Since the initiNone  Time frame: par	
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).  Royalties or licenses	needed) Time frame: Since the initiNone  Time frame: par	
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).  Royalties or licenses	needed) Time frame: Since the initiNone  Time frame: par	
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).  Royalties or licenses	needed)  Time frame: Since the initi None  Time frame: parNone	
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).  Royalties or licenses  Consulting fees	needed) Time frame: Since the initiNone  Time frame: par	
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).  Royalties or licenses	needed)  Time frame: Since the initi None  Time frame: parNone	

	HELD & I DOIGHT LEUCK SHEE	THREE STATES OF STREET, STATES	A to this measurement unitherest transference transfer for all prince
	financial interests	a the carried morths.	ON THE STATE COMPANY OF STREET, WAS TAKING THE STATE OF T
13	Other financial or non-	None	
	writing, gifts or other services	Name all entities with	Specifications/Comments
12	Receipt of equipment, materials, drugs, medical	<u>√</u> None	le.e., if payments were made to you or to your Institution)
11	Stock or stock options	None	
Ţ	in other board, society, committee or advocacy group, paid or unpaid	V None	
10	Leadership or fiduciary role	None	
	Safety Monitoring Board or Advisory Board		
9	Participation on a Data	None	
	pending	100-100-07	
8	Patents planned, issued or	None	
	any antity (if not indicated in Rem #1 abova).		
	Protestine of the modern and the second seco	A Atalis	
7	Support for attending meetings and/or travel	None	
	Consulting fees feetimonal		
6	Payment for expert testimony	None	
	speakers bureaus, manuscript writing or educational events		
5	Payment or honoraria for lectures, presentations,	None	

Please summarize the above conflict of interest in the following box: with a manufacture of summarize the above conflict of interest in the following box:

I have no conflicts of interven	est to declare
parties whose interests may be affected by the content of the manu- to transparency and does not necessarily indicate a bias. If you are intelligible that you do so,	
related to the content of your manuscript. "Related" means any relaters whose Interests may be affected by the content of the manu	July to their

Please place an "X" next to the following statement to indicate your agreement:

Pate: 2022-2-22				
	zhao		TOTA In 1200	benefitied
Januscrint Title: Advanced	lung adenocarcinoma	patient	With EGFR mutations	targeted th
Manuscript number (if known):			multiline combination after osimertinib	10
n the interest of transparency, elated to the content of your n parties whose interests may be to transparency and does not n relationship/activity/interest, i	nanuscript. "Related" mean affected by the content of ecessarily indicate a bias.	the manuso	ript. Disclosure represents	a commitment
he following questions apply t	to the author's relationship	os/activities,		
The author's relationships/action the epidemiology of hypertemedication, even if that medican item #1 below, report all supthe time frame for disclosure is	ension, you should declare ation is not mentioned in t oport for the work reporte	he manuscr	pt.	,
Other financial or non-				
2 Peccept of equipment, materials, drugs, medical writing, gifts of other	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specification (e.g., if pay institution)	ns/Comments ments were made to you or to	your
	Time frame: Since the initia	l planning of	the work	
All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None			
	Time frame: pas	t 36 months		
2 Grants or contracts from any entity (if not indicated in item #1 above).	None			
3 Royalties or licenses	None			
A Consulting food	None			
4 Consulting fees	* NOTA			
* anystriat writing or * anystriat writing or * ducational events				

5	Payment or honoraria for	<u>√</u> None	
	lectures, presentations, speakers bureaus,	4	
	manuscript writing or educational events		
6	Payment for expert	None	
	testimony		
	consulting fees	Mone	
7	Support for attending meetings and/or travel	None	
	ROMETER OF PERSONS	Mone	
	any easity (dinot indicated in Hernik) above.		
8	Patents planned, issued or	None	
	pending	Tipie rame pa	So so manths, 1914 19
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society, committee or advocacy		
	group, paid or unpaid	_ None	
11	Stock or stock options	None	
		the same than an	
12	Receipt of equipment,	None	Institution)
	materials, drugs, medical	whom you have this	(e.g., it payments were made to you or to your
	writing, gifts or other services	Name all entitles with	Specifications/Comments
13	Other financial or non-	None	
113	financial interests	rine par comening	
115	omin we protoke retroit on an	ibott tot rus metr tehra	CALIN AND MEMBERSONE AMBROAS AMBROAS AND SOLVE OF SELECTION OF SELECTI

Please summarize the above conflict of interest in the following box:

I have no conflicts of interest to declare

Xnegi Zhar

数質現

Please place an "X" next to the following statement to indicate your agreement:

Date: 2022-2-22						
Your Name: Jinlin wang						
Manuscript Title: Advanced Lung adenocarcinoma	patient	patient	with	EGFR	mutations	benefin
Manuscript number (if known): 47m-22-91-M5-6418	upr gusa en	from multi	line co	mbinati	ion targete	d therap
		after osim	ertinib	Vesistan	ice: a ca	se repo

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

315	Receipt of equienters materials, dr. ex, aredical writing places other	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
10	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	
		Time frame: pas	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	_V_None	
4	Consulting fees	None	

5	Payment or honoraria for		
	lectures, presentations,		
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert	None	
	testimony		
寸	Consulting fees	1/ None	
7	Support for attending meetings and/or travel	None	
	Actorial certains	11 - 41 - 125	
	not established addressed		
8	Patents planned, issued or pending	None	
9	Participation on a Data	None	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role in other board, society,	None	
	committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	<u> </u>	Andrew Herrory Conservation and the second s
12	Receipt of equipment,	✓ None	Instantion)
	materials, drugs, medical writing, gifts or other	Marie ali entities with whom you have this	Specifications/Comments  (e.g., if payments were made to you or to your
	services		
13	Other financial or non- financial interests	None	
	TOUR AND PROPERTY OF THE PROPE	there ice are some charge	en de la de la compositione manifestat desta mante la composition de

Please summarize the above conflict of interest in the following box:

<b>75</b> 07								
1	have	no	conflicts	of	interest	to	declare	
arth arth			s may be affecte bes not necessari				Jinlin	Wang 王金林

Please place an "X" next to the following statement to indicate your agreement:

Your Name: Fang fang A Manuscript Title: Advance Manuscript number (if known)		multiline combination targeted theraps
Manuscript Title: Advance Manuscript number (if known)		multiline combination targeted therap
Manuscript Title: Advance Manuscript number (if known)		multiline combination targeted therap
		after oximertinib resistance: a case
related to the content of your parties whose interests may be to transparency and does not relationship/activity/interest,  The following questions apply manuscript only.  The author's relationships/act	manuscript. "Related" me e affected by the content necessarily indicate a bias it is preferable that you d to the author's relationsh civities/interests should be ension, you should declar	nips/activities/interests as they relate to the <u>current</u> e <u>defined broadly</u> . For example, if your manuscript pertaine all relationships with manufacturers of antihypertensive
In item #1 below, report all su the time frame for disclosure i		ed in this manuscript without time limit. For all other ite
APRILIE ARTHUR DE HOLIMA	Name all entities with	Specifications/Comments
heselpt of aquiomans,	whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your institution)
	Time frame: Since the initi	al planning of the work
All support for the present	None	
manuscript (e.g., funding,		
provision of study materials,	T place	
medical writing, article		
medical writing, article processing charges, etc.)		
medical writing, article	A series	
medical writing, article processing charges, etc.)	Time frame: pas	

any entity (if not indicated

**V** None

None

in item #1 above).
Royalties or licenses

Consulting fees

4

5	Payment or honoraria for	<u>V</u> None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
Ą	Consulting fees	None	
7	Support for attending	None	
	meetings and/or travel		
	GOARGIRA OL ROLLINES	Table 1	
	(n man #1 nagye)		
	any antity (if any indicated		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	<u>✓</u> None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy	√ None	
- Inches	group, paid or unpaid		
11	Stock or stock options	<u>V</u> None	
		(RECEIVE)	
		AND THE PROPERTY OF THE PROPER	
12	Receipt of equipment,	None	AODL TO
	materials, drugs, medical	Sizing all entities with Specifications/Comments	
	writing, gifts or other services		
13	Other financial or non-	None	
12	financial interests	TO NOTE	
	THICH COLD THE COLD T	BOOK TO THE MORK LEBOURS THE EAST BEST HISTORIES AND THOSE BURE	LOUGH TOTAL

Please summarize the above conflict of interest in the following box: Please summarize the above conflict of interest in the following box:

I have	No abbja	conflicts	of	interest	to	declare
o transparency and doe elatlonship/activity/int				on go so Far	yfan	9 Lin
sittles whose interests					刘士	

Please place an "X" next to the following statement to indicate your agreement:

n the elate o trainelation the formanu	ed to the content of your es whose interests may lead to the insparency and does not conship/activity/interest collowing questions apply script only.	y, we ask you to disclose a manuscript. "Related" more affected by the content necessarily indicate a bias, it is preferable that you details.	multifine combination targeted after osimertinis a case report all relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment s. If you are in doubt about whether to list a do so.  hips/activities/interests as they relate to the current
n the elate o trainelation for the formanu	interest of transparence to to the content of your es whose interests may lead to the content of your es whose interests may lead to the conship/activity/interest ollowing questions apply script only.	y, we ask you to disclose a manuscript. "Related" more affected by the content necessarily indicate a bias, it is preferable that you details.	after osimertinibia case reportal relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment s. If you are in doubt about whether to list a do so.
elate o tra elation The formanu The au o the	ed to the content of your es whose interests may lead to the insparency and does not conship/activity/interest collowing questions apply script only.	r manuscript. "Related" mobe affected by the content necessarily indicate a bias , it is preferable that you d	all relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment s. If you are in doubt about whether to list a do so.
elate partie o tra- elation The formanu The au o the	ed to the content of your es whose interests may lead to the insparency and does not conship/activity/interest collowing questions apply script only.	r manuscript. "Related" mobe affected by the content necessarily indicate a bias , it is preferable that you d	eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment s. If you are in doubt about whether to list a lo so.
he ac	script only. uthor's relationships/ac	y to the author's relations	nips/activities/interests as they relate to the current
the			
	cation, even if that med	ication is not mentioned in upport for the work report	re all relationships with manufacturers of antihypertensiven the manuscript.  The ted in this manuscript without time limit. For all other items
AN N	aceuti of equipment, artenais drugs, madeal rath a gifts of other ervices	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
m pr	I support for the present anuscript (e.g., funding, ovision of study materials,	per construction of the second	
pr No	edical writing, article occessing charges, etc.) time limit for this item.	None	
		Time frame: pa	st 36 months
ar	rants or contracts from ny entity (if not indicated item #1 above).	None	
	oyalties or licenses	None	
Co	onsulting fees	None	
	fucational events eyment for expert.	∠_None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
	Payment for expert testimony	None	
	counting 1993	ZZyjoue	
7	Support for attending meetings and/or travel	None	
	potransi or gosuste	1 19946	
	any emity (if not indicated in demitt abova).		
8	Patents planned, issued or pending	None	a ap uiduanz a san a san an a
	perioring	7	
9	Participation on a Data Safety Monitoring Board or	None	
	Advisory Board		
10	Leadership or fiduciary role in other board, society,	None	
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	Vone	
••	Stock of Stock options		
2	Receipt of equipment,	None or indicate	institution)
	materials, drugs, medical	valuom you have this	(e.g., if payments were made to you or to your
	writing, gifts or other services	Name all entities with	Specifications/Comments
13	Other financial or non-	<u>✓</u> None	
	financial interests	the part 35 months	
	CONTROPON REPORT BIT SE	DOLL FOR THE WORK TREAT	les he this manuscript withour time limit. For all orde

Please summarize the above conflict of interest in the following box:

I have	No	conflicts	of	unterest	to	declare
lationship/activity/lot						1-1, Zhang
irties whose Interests transparency and doe						HAMA Zo

Please place an "X" next to the following statement to indicate your agreement:

Date	e: 2022-1-22		
	r Name: Yuan Ch	ren/	
Vlan	nuscript Title: Advanced	my adenocarcinoma	partied with EGIR mutations benefitied from mutilize a
/lan	nuscript number (if knowr	n): ATM-22-971-mg-64296	turgethed therap in offer as
			veristance: a case report
arti o tr	ied to the content of your ies whose interests may be ansparency and does not tionship/activity/interest	r manuscript. "Related" mode affected by the content in necessarily indicate a biast, it is preferable that you content in the preferable the preferable that you content in the preferable tha	all relationships/activities/interests listed below that are leans any relation with for-profit or not-for-profit third to f the manuscript. Disclosure represents a commitment s. If you are in doubt about whether to list a do so.  hips/activities/interests as they relate to the current
an	uscript only.	to the author s relations	imps, activities/interests as they relate to the <u>current</u>
ieai	em #1 below, report all su	cation is not mentioned in upport for the work report	re all relationships with manufacturers of antihypertension the manuscript.  ted in this manuscript without time limit. For all other ited
e t	ime frame for disclosure	is the past 36 months.	
ne t	ime frame for disclosure	Name all entities with	Specifications/Comments
et	ime frame for disclosure	is the past 36 months.	
et	ime frame for disclosure	Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
Ampim	all support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Ampim	all support for the present nanuscript (e.g., funding, provision of study materials, nedical writing, article rocessing charges, etc.)	Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initi	Specifications/Comments (e.g., if payments were made to you or to your institution)  al planning of the work
A m p m p l N	all support for the present manuscript (e.g., funding, provision of study materials, medical writing, article rocessing charges, etc.) to time limit for this item.	Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)  al planning of the work
A mp m pi N	all support for the present manuscript (e.g., funding, rovision of study materials, medical writing, article rocessing charges, etc.) to time limit for this item.  Trants or contracts from my entity (if not indicated item #1 above).	Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initiation of the init	Specifications/Comments (e.g., if payments were made to you or to your institution)  al planning of the work
A mp m pi N	all support for the present manuscript (e.g., funding, provision of study materials, medical writing, article rocessing charges, etc.) to time limit for this item.	Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initiative None	Specifications/Comments (e.g., if payments were made to you or to your institution)  al planning of the work
A m p m p m p m p n N Ccc	all support for the present manuscript (e.g., funding, rovision of study materials, medical writing, article rocessing charges, etc.) to time limit for this item.  Trants or contracts from my entity (if not indicated item #1 above).	Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initiation of the init	Specifications/Comments (e.g., if payments were made to you or to your institution)  al planning of the work

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
4	Consulting fees	L None	
7	Support for attending meetings and/or travel	<u>None</u>	
	COASTITE COMMITTEE	77248	
	IN FIGURES BODARS	The same of the sa	
	any antity til not indicated		
8	Patents planned, issued or	None	
	pending		ACTIVITY OF THE PROPERTY OF TH
9	Participation on a Data Safety Monitoring Board or	None	
	Advisory Board	Language and the second second second	
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy group, paid or unpaid	Тумоне	
11	Stock or stock options	None	- Designation of the property of the state o
	Stock of Stock options	-V None	
		0015 (300 toxe 32	
12	Receipt of equipment,	None	[nstitution]
	materials, drugs, medical	wham you have this	(e.g., if payments were made to you or to your
	writing, gifts or other	Name all entitles with	Specifications/Comments
10	services	None -	
13	Other financial or non- financial interests	None	
	iniancial interests	PERCENT FOR STATE OF THE PROPERTY OF THE PERCENT OF	AND THE FIRST REPORTED AND THE BRUTTHANK THREE LIFERED TO BE AND THE PARTY.

Please summarize the above conflict of interest in the following box: plbs App usual scribes of supply become a supply and a supply supply approximate the above conflict of interest in the following box:

I have no conflicts of netwest to declare.	ey relate to the <u>curren</u>
arries whose interests may be affected by the content of the manuscript. Disclosure transparency and does not necessarily indicate a bias. If you are in a familiar classical properties of the familiar content of the manuscript of the content of the manuscript. Disclosure is transparency and does not necessarily indicate a bias. If you are in a familiar classical content of the manuscript. Disclosure is transparency and does not necessarily indicate a bias. If you are in a familiar classical content of the manuscript. Disclosure is transparency and does not necessarily indicate a bias. If you are in a familiar classical content of the manuscript. Disclosure is transparency and does not necessarily indicate a bias. If you are in a familiar classical content of the manuscript.	
elated to the content of your manuscript. "Related" means any relation with for pre- sarties whose interests may be affected by the content of the manuscript. Disclosure	がか

Please place an "X" next to the following statement to indicate your agreement:

1a	anuscript Title: <u>Ackances</u>	- //	arcinoma patient will EGFR mutations
-	anuscript number (if known)	): ATM-82-971-115-6428	from multiline Combination
			-Clerapies after osimerti -Ce: a case report
			all relationships/activities/interests listed below that are
	ated to the content of your rties whose interests may be	manuscript. "Related" me e affected by the content necessarily indicate a bias	eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment s. If you are in doubt about whether to list a
	e following questions apply anuscript only.	to the author's relationsh	nips/activities/interests as they relate to the current
e	the epidemiology of hyperto edication, even if that medic	ension, you should declar cation is not mentioned in pport for the work report	e defined broadly. For example, if your manuscript pertage all relationships with manufacturers of antihypertension the manuscript.  The manuscript without time limit. For all other items
	services	Name all autota della	[ C
The second secon	Nace of all numbers of most most, most man, analy, most man, analy, most of most most man, and many most of most most most man, and many most most most most most most most most	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
l		Time frame: Since the initi	al planning of the work
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article	None	
	No time limit for this item.	( Name	
		Time frame: pas	st 36 months
	Grants or contracts from any entity (if not indicated in item #1 above).	None	
	Royalties or licenses	None	
	DIMERCAL COMPONENTS		
	Sulpress to social	77. (8.02.19	
	Consulting fees	None	
-	16tinzouA.		The state of the s
The same of the sa	Payment for expert. testimony	1. None	

5	Payment or honoraria for		
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
ď	Consulting fees	A None	
7	Support for attending meetings and/or travel	None	
	in Jeen #1 above)	1551.00	
	any entity (it not indicated		
8	Patents planned, issued or	<u>V</u> None	
	pending		
9	Participation on a Data Safety Monitoring Board or	None	
	Advisory Board		
10	Leadership or fiduciary role	<u>✓</u> None	
	in other board, society,		
	committee or advocacy group, paid or unpaid	Vione	
11	Stock or stock options	V None	
		\$440Q6Q	
		是我们是"自己在"ADMA"在第一	
12	Receipt of equipment,	None	nstitutioni
	materials, drugs, medical	whom you have this	a.s., if payments were made to you of to your
	writing, gifts or other	Marrie all entities with	sedifications/Comments
	services		
13	Other financial or non-	None	
	financial interests	E 8 180 COMES 190 BACASTALISE	
	TOTAL ST. DOLONE, LEBOY SESSI	BOND OF BIG WORK SHOULD	A SUIT MEMORIES OF MACHINES DOWN THEM SEED OF DESIGN

Please summarize the above conflict of interest in the following box: Who MISS WESTERNESS OF SUCCESSION SERVICES O

gniwallo	dogsgous		11:14	of interest	to local	Curo
russuuht s	newe	no c	onfuces	of meeter	go quen	1
				bias. If you are in	Qio	n chu

Please place an "X" next to the following statement to indicate your agreement: